Ensign Peak Advisors
ABBV icon

Ensign Peak Advisors’s AbbVie ABBV Stock Holding History

Ensign Peak Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267M Sell
1,226,870
-786,118
-39% -$174M 0.5% 37
2025
Q4 		$460M Sell
2,012,988
-31,575
-2% -$7.19M 0.81% 17
2025
Q3 		$473M Sell
2,044,563
-109,443
-5% -$22.3M 0.78% 18
2025
Q2 		$400M Buy
2,154,006
+31,590
+1% +$5.87M 0.68% 21
2025
Q1 		$445M Buy
2,122,416
+63,027
+3% +$12.3M 0.85% 18
2024
Q4 		$366M Buy
2,059,389
+29,697
+1% +$5.46M 0.65% 25
2024
Q3 		$401M Sell
2,029,692
-44,209
-2% -$8.25M 0.7% 23
2024
Q2 		$356M Sell
2,073,901
-28,733
-1% -$4.76M 0.65% 27
2024
Q1 		$383M Buy
2,102,634
+127,034
+6% +$21.9M 0.7% 22
2023
Q4 		$306M Sell
1,975,600
-360,985
-15% -$52.6M 0.61% 34
2023
Q3 		$348M Buy
2,336,585
+525,155
+29% +$77.1M 0.74% 26
2023
Q2 		$244M Sell
1,811,430
-727,009
-29% -$107M 0.49% 48
2023
Q1 		$405M Sell
2,538,439
-331,094
-12% -$50.6M 0.88% 19
2022
Q4 		$464M Buy
2,869,533
+35,399
+1% +$5.43M 1.04% 13
2022
Q3 		$380M Sell
2,834,134
-842,306
-23% -$121M 0.94% 18
2022
Q2 		$563M Buy
3,676,440
+326,206
+10% +$49.8M 1.34% 8
2022
Q1 		$543M Buy
3,350,234
+623,629
+23% +$90.6M 1.1% 11
2021
Q4 		$369M Buy
2,726,605
+474,301
+21% +$56M 0.71% 25
2021
Q3 		$243M Buy
2,252,304
+530,612
+31% +$60.6M 0.51% 41
2021
Q2 		$194M Buy
1,721,692
+107,162
+7% +$12.1M 0.39% 70
2021
Q1 		$175M Buy
1,614,530
+56,783
+4% +$6.07M 0.38% 72
2020
Q4 		$167M Buy
1,557,747
+701,069
+82% +$67.4M 0.38% 62
2020
Q3 		$75M Buy
856,678
+156,569
+22% +$14.7M 0.19% 104
2020
Q2 		$68.7M Buy
700,109
+322,921
+86% +$28.4M 0.19% 100
2020
Q1 		$28.7M Sell
377,188
-102,289
-21% -$8.71M 0.1% 161
2019
Q4 		$42.5M Buy
+479,477
New +$39.8M 0.11% 151

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors's ABBV Position: Q1 2026 in Review

Ensign Peak Advisors reduced its AbbVie (ABBV) stake by 39% in Q1 2026, selling an estimated $174M and leaving 1,226,870 shares worth $267M. The position accounts for 0.5% of the portfolio, ranked #37.

Ensign Peak Advisors first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $563M in Q2 2022. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Ensign Peak Advisors held 1,226,870 shares of AbbVie worth $267M as of Q1 2026.
  • Ensign Peak Advisors sold 786,118 AbbVie shares in Q1 2026, an estimated $174M.
  • AbbVie made up 0.5% of Ensign Peak Advisors's portfolio in Q1 2026, its #37 holding.
  • Ensign Peak Advisors first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's AbbVie position peaked at $563M in Q2 2022.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.